G
Gerald V. Doyle
Researcher at University of Michigan
Publications - 45
Citations - 14673
Gerald V. Doyle is an academic researcher from University of Michigan. The author has contributed to research in topics: Circulating tumor cell & Metastatic breast cancer. The author has an hindex of 24, co-authored 45 publications receiving 13602 citations. Previous affiliations of Gerald V. Doyle include University of Texas MD Anderson Cancer Center & Johnson & Johnson.
Papers
More filters
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.
Journal ArticleDOI
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Steven J. Cohen,Cornelis J A Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. Craig Miller,Gerald V. Doyle,H. Tissing,Leon W.M.M. Terstappen,Neal J. Meropol +13 more
TL;DR: The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer and Baseline and follow-up CTC levels remained strong predictors of P FS and OS after adjustment for clinically significant factors.
Journal ArticleDOI
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Massimo Cristofanilli,Daniel F. Hayes,G. Thomas Budd,Mathew J. Ellis,A. Stopeck,James M. Reuben,Gerald V. Doyle,Jeri Matera,W. Jeffrey Allard,M. Craig Miller,Herbert A. Fritsche,Gabriel N. Hortobagyi,Leon W.M.M. Terstappen +12 more
TL;DR: In this article, the authors investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-free survival (PFS), and overall survival (OS) in patients with newly diagnosed metastatic breast cancer who were about to start first-line therapy.
Journal ArticleDOI
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Daniel F. Hayes,Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,A. Stopeck,M. Craig Miller,Jeri Matera,W. Jeffrey Allard,Gerald V. Doyle,Leon W.W.M. Terstappen +9 more
TL;DR: In this paper, the authors reported that ≥5 circulating tumor cells (CTC) in 7.5 mL blood at baseline and at first follow-up in 177 patients with metastatic breast cancer (MBC) were associated with poor clinical outcome.